Detalles de la búsqueda
1.
Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria.
Am Heart J
; 270: 125-135, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38367893
2.
Effects of Dapagliflozin in Chronic Kidney Disease Across the Spectrum of Age and by Sex.
J Gen Intern Med
; 39(6): 921-930, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38097862
3.
Glomerular and tubular effects of dapagliflozin, eplerenone and their combination in patients with chronic kidney disease: A post-hoc analysis of the ROTATE-3 study.
Diabetes Obes Metab
; 26(2): 576-582, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37926904
4.
Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease : A Post Hoc Analysis of DAPA-CKD.
Ann Intern Med
; 176(1): 59-66, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36469914
5.
Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression.
J Am Soc Nephrol
; 34(12): 2025-2038, 2023 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37872654
6.
Validity and Utility of a Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression: A Review.
J Am Soc Nephrol
; 34(12): 1928-1935, 2023 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37807165
7.
Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials.
J Am Soc Nephrol
; 34(12): 1965-1975, 2023 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37876229
8.
Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease.
Kidney Int
; 104(6): 1219-1226, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37657768
9.
Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials.
Kidney Int
; 104(1): 181-188, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37119876
10.
Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial.
Cardiovasc Diabetol
; 22(1): 330, 2023 11 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38017482
11.
Albuminuria-lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross-over clinical study.
Diabetes Obes Metab
; 25(6): 1758-1768, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36843215
12.
Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials.
Diabetes Obes Metab
; 25(11): 3327-3336, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37580309
13.
Overall and inter-individual effect of four different drug classes on soluble urokinase plasminogen activator receptor in type 1 and type 2 diabetes.
Diabetes Obes Metab
; 25(11): 3152-3160, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37417375
14.
Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial.
J Am Soc Nephrol
; 33(8): 1569-1580, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35440501
15.
Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD.
J Am Soc Nephrol
; 33(11): 2094-2107, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35977807
16.
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
Diabetologia
; 65(7): 1085-1097, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35445820
17.
Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease.
Circulation
; 143(5): 438-448, 2021 02 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33186054
18.
Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure.
Cardiovasc Diabetol
; 21(1): 194, 2022 09 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-36151557
19.
Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial.
Nephrol Dial Transplant
; 37(9): 1647-1656, 2022 08 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-34850160
20.
Quételet (body mass) index and effects of dapagliflozin in chronic kidney disease.
Diabetes Obes Metab
; 24(5): 827-837, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34984791